The state of deprescribing research: How did we get here?

Reeve, Emily; Thompson, Wade; Boyd, Cynthia M.; Lundby, Carina; Steinman, Michael A.

doi:10.1111/bcpt.13862

Cited by 6 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coined in 2003, the term "deprescribing" has witnessed significant growth in usage, research, and the development of supporting networks, and has gained particular momentum since 2016. 19 This evolution highlights the growing acknowledgment of deprescribing as a crucial strategy in optimizing drug treatment regimens to meet the specific needs and goals of individual patients. Concurrently, the substantial growth in randomized controlled trials evaluating deprescribing interventions attests to the increasing emphasis on evidence based approaches.…”

Section: Introductionmentioning

confidence: 99%

Deprescribing in older adults with polypharmacy

Hung,

Kim,

Pavon

2024

BMJ

View full text Add to dashboard Cite

Polypharmacy is common in older adults and is associated with adverse drug events, cognitive and functional impairment, increased healthcare costs, and increased risk of frailty, falls, hospitalizations, and mortality. Many barriers exist to deprescribing, but increased efforts have been made to develop and implement deprescribing interventions that overcome them. This narrative review describes intervention components and summarizes findings from published randomized controlled trials that have tested deprescribing interventions in older adults with polypharmacy, as well as reports on ongoing trials, guidelines, and resources that can be used to facilitate deprescribing. Most interventions were medication reviews in primary care settings, and many contained components such as shared decision making and/or a focus on patient care priorities, training for healthcare professionals, patient facing education materials, and involvement of family members, representing great heterogeneity in interventions addressing polypharmacy in older adults. Just over half of study interventions were found to perform better than usual care in at least one of their primary outcomes, and most study interventions were assessed over 12 months or less.

show abstract

Section: Introductionmentioning

confidence: 99%

Deprescribing in older adults with polypharmacy

Hung,

Kim,

Pavon

2024

BMJ

View full text Add to dashboard Cite

show abstract

“…Three papers provide an overview of existing deprescribing research and future perspectives in the field. Reeve et al 1 discuss current state of knowledge in deprescribing research within four main areas, including establishing the healthcare issues that deprescribing research aims to address, exploring why these issues exist, developing resources and tools to address these issues and fixing them through interventional and implementation research. Steinman 2 discusses learnings from existing deprescribing research and provides six recommendations for how the field can continue to grow.…”

mentioning

confidence: 99%

Advancing deprescribing: Learnings from the first international conference on deprescribing

Lundby,

Thompson

2023

Basic Clin Pharma Tox

Self Cite

View full text Add to dashboard Cite

“…As we embark on the new year, we invite you to explore the wealth of knowledge and exciting content our journal offers. In 2023, we published three Special Collections from focused conferences supported by the Nordic Association for the Publication of Basic and Clinical Pharmacology and Toxicology, including Adhesion G‐Protein‐coupled Receptors, 1–10 Transmembrane Transporter Proteins: Catching Transport in Motion 11–19 and Advancing Deprescribing: Learnings from the first International Conference on Deprescribing 20–31 . The second part of the latter Special Collection will appear in the January 2024 issue.…”

mentioning

confidence: 99%

Welcome to Basic & Clinical Pharmacology & Toxicology 2024

Simonsen,

Lykkesfeldt

2023

Basic Clin Pharma Tox

View full text Add to dashboard Cite

a 1500 euro grant to a scientific meeting of their own choice.In addition to these exciting Special Collections, we have each month appointed Editor's choice; an example is our August choice addressing Geographical variation in persistence to oral anticoagulation therapy and clinical outcomes among patients with atrial fibrillation initiating therapy in Denmark, Sweden, Norway, and Finland. 36 In addition to the journal, our SoMe Editor, Carina Lundby, works daily to promote our content on 'X', LinkedIn and WeChat. Therefore, we also invite you to follow Basic & Clinical Pharmacology & Toxicology online and promote your own articles.The revenue of the journal is used by the Association for the Publication of BCPT to support scientific meetings in the Nordic countries and to extend the financial resources to make it possible to sponsor events with a Nordic footprint and commitment in other locations. Announcements of application calls can be found on our website. The BCPT Nordic Prize 2023 was awarded to

show abstract

The state of deprescribing research: How did we get here?

Cited by 6 publications

References 18 publications

Deprescribing in older adults with polypharmacy

Deprescribing in older adults with polypharmacy

Advancing deprescribing: Learnings from the first international conference on deprescribing

Welcome to Basic & Clinical Pharmacology & Toxicology 2024

Contact Info

Product

Resources

About